Shek Man Chim joined Regeneron Pharmaceuticals in 2018 and has been a Principal Scientist since 2022. Before his current appointment, he was a Research Fellow at the Harvard School of Dental Medicine (2014–2018). He graduated from The University of Western Australia, received his Ph.D. in Biological Sciences (2009), and then became a Research Associate (2010–2014). He also holds a B.S. in Biology from The Hong Kong University of Science and Technology (2003).
Brian Zambrowicz joined Regeneron Pharmaceuticals in 2015 and serves as Executive Vice President of Functional Genomics and Chief of VelociGene® operations. Before joining Regeneron, he held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Before joining Lexicon, he served as a National Institutes of Health postdoctoral fellow at the Fred Hutchinson Cancer Center in Seattle, Washington, where he studied gene trapping and gene targeting technology. He received his B.S. from the University of Wisconsin and Ph.D. from the University of Washington, both in biochemistry.
Katia Karalis joined Regeneron Pharmaceuticals Inc. as an Executive Director of Research and Development in 2020. Before her appointment at Regeneron, she was an Executive Vice President for Research and Development at Emulate, Inc., a Faculty at the Boston Children's Hospital, a Researcher, Director, and Professor at the Biomedical Research Foundation of the Academy of Athens, a Visiting Scholar at the Wyss Institute for Biologically Inspired Engineering, and a Helmholtz Fellow. She was trained in Clinical Molecular Genetics at Harvard University. She is an expert in micro-physiological systems, for which her team has developed models for human liver, intestine, brain, lung, and BBB diseases, and in preclinical and translational research for inflammatory and metabolic diseases. She holds an M.D. and a Ph.D. in Physiology and Philosophy from the University of Athens.
Elias Pavlopoulos joined Regeneron Pharmaceuticals, Inc., in 2017. He held roles of increasing responsibility and became Associate Director of Research and Development in 2021. He also serves as a member of the Scientific Advisory Board of Tessara Therapeutics Pty Ltd. Before joining Regeneron, he served as a Senior Scientist at Acorda Therapeutics, Inc., an Associate Research Scientist at Columbia University in the laboratory of Eric Kandel, and a postdoctoral fellow at Texas A&M University. He graduated from Aristotle University of Thessaloniki (AUTH) and earned his M.Sc. and Ph.D. in Molecular Biology and Genetics at the University of Crete and the Institute of Molecular Biology and Biotechnology (IMBB-FORTH). His areas of expertise encompass ALS, FTD, Huntington’s disease, multiple sclerosis, and the molecular mechanisms underlying learning, memory, and human cognitive aging.
